Effectiveness of first‐line cetuximab in wild‐type RAS metastatic colorectal cancer according to tumour BRAF mutation status from the EREBUS cohort

Aims Poor efficacy has been reported for patients with BRAF mutations for metastatic colorectal cancer (mCRC). Methods EREBUS is a French cohort study of wild‐type (wt) KRAS unresectable mCRC patients initiating a first‐line treatment with cetuximab from 2009 to 2010, followed for two years (five ye...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	British journal of clinical pharmacology 2021-03, Vol.87 (3), p.1120-1128
Hauptverfasser:	Rouyer, Magali, François, Eric, Sa Cunha, Antonio, Monnereau, Alain, Bignon, Emmanuelle, Jové, Jérémy, Lassalle, Régis, Droz‐Perroteau, Cécile, Moore, Nicholas, Noize, Pernelle, Fourrier‐Réglat, Annie, Smith, Denis
Format:	Artikel
Sprache:	eng
Schlagworte:	anticancer drugs Antineoplastic Combined Chemotherapy Protocols cancer Cetuximab - therapeutic use Cohort Studies Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics genotyping Humans Male Mutation Neoplasm Metastasis pharmacoepidemiology Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins p21(ras)
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!